You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 9, 2025

Drug Price Trends for NDC 82829-0002


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 82829-0002

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
IZERVAY 2MG/0.1ML SOLN,OPH Astellas Pharma U.S., Inc. 82829-0002-01 1 1571.94 1571.94000 2023-12-01 - 2026-09-29 FSS
IZERVAY 2MG/0.1ML SOLN,OPH Astellas Pharma U.S., Inc. 82829-0002-01 1 1568.84 1568.84000 2024-03-15 - 2026-09-29 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for the Drug NDC: 82829-002

Introduction

The drug with the NDC code 82829-002, identified as IZERVAY (avacincaptad pegol intravitreal solution), is a recently approved medication by the FDA, receiving its initial U.S. approval in 2023. This analysis will delve into the market context, pricing trends, and projections for this drug.

Market Context

Drug Overview

IZERVAY is an intravitreal solution used for specific ocular conditions. It is supplied as a sterile, clear to slightly opalescent, colorless to slightly yellowish solution with a concentration of 20 mg/mL[1].

Competitive Landscape

The ophthalmic drug market is highly competitive, with various treatments available for different ocular conditions. IZERVAY's unique mechanism and approval for specific indications position it as a significant player in this market.

Pricing Trends

Current Pricing

As a newly approved drug, IZERVAY's pricing is influenced by several factors, including its novelty, the severity of the conditions it treats, and the lack of generic alternatives. The wholesale acquisition cost (WAC) for such specialized drugs is typically high due to the complex manufacturing process and the limited patient population.

Global Pricing Comparisons

In the U.S., drug prices are significantly higher compared to other regions. For instance, prices in the U.S. are 5.5 times those in the OECD (excluding the U.S.) and 7.7 times prices in the rest of the world (excluding the U.S.) for similar drugs[3].

Price Projections

General Drug Price Inflation

The overall drug price inflation rate is projected to be around 3.81% for 2025, according to Vizient's summer Pharmacy Market Outlook. This projection is influenced by factors such as expanding indications for previously approved medications and the introduction of high-cost cell and gene therapies[2].

Specific to IZERVAY

Given the specialized nature of IZERVAY and its recent approval, it is likely that its price will remain high in the short to medium term. Here are a few factors that could influence its pricing:

Market Demand and Competition

As more patients are diagnosed and treated with IZERVAY, demand could increase, potentially stabilizing or even increasing its price if there are no significant competitors.

Regulatory and Transparency Efforts

Efforts to increase transparency and regulate drug prices, such as those seen in Oregon's Drug Price Transparency Program, could impact the pricing strategy for IZERVAY. However, these efforts are still in their early stages and may not immediately affect newly approved drugs[5].

Healthcare Policy Changes

Policy changes, such as the Inflation Reduction Act of 2022, which allows Medicare to negotiate prices for certain drugs, could have a broader impact on the pharmaceutical industry. However, these changes are unlikely to affect IZERVAY's pricing in the immediate future[5].

Adverse Reactions and Safety Profile

The safety profile of IZERVAY, including common ocular adverse reactions such as blurred vision, conjunctival hemorrhage, and increased intraocular pressure, may also influence its pricing. A favorable safety profile could support higher pricing due to its value proposition in treating severe ocular conditions[1].

Economic Impact

Healthcare Spending

The introduction of high-cost drugs like IZERVAY contributes to the overall increase in healthcare spending. For instance, recently approved gene therapies range from $2 million to $4.25 million per dose, significantly impacting provider budgets and operational processes[2].

Patient Access and Affordability

The high cost of IZERVAY may limit patient access, especially in regions with less robust healthcare systems or insurance coverage. This could lead to discussions around affordability and potential price adjustments or assistance programs to make the drug more accessible.

Conclusion on Pricing Projections

Given the current market trends and the specialized nature of IZERVAY, it is likely that its price will remain high in the near future. Here are some key points to consider:

  • Short-term Stability: The price of IZERVAY is expected to remain stable or slightly increase due to its novelty and the lack of direct competitors.
  • Long-term Adjustments: As more data becomes available on its efficacy and safety, and as regulatory and transparency efforts evolve, there could be adjustments to its pricing strategy.
  • Market and Policy Influences: Broader market trends, including drug price inflation and healthcare policy changes, will continue to influence the pricing of IZERVAY.

Key Takeaways

  • IZERVAY is a recently approved intravitreal solution for specific ocular conditions.
  • The drug's pricing is influenced by its novelty, the severity of the conditions it treats, and global pricing trends.
  • The overall drug price inflation rate is projected to be around 3.81% for 2025.
  • Regulatory and transparency efforts may impact the pricing strategy in the long term.
  • The high cost of IZERVAY could limit patient access and contribute to increased healthcare spending.

FAQs

What is IZERVAY used for?

IZERVAY (avacincaptad pegol intravitreal solution) is used for the treatment of specific ocular conditions, as approved by the FDA in 2023.

How is IZERVAY priced compared to other drugs?

IZERVAY's pricing is expected to be high due to its specialized nature and the lack of generic alternatives. It follows the general trend of high drug prices in the U.S. compared to other regions.

What are the common adverse reactions associated with IZERVAY?

Common ocular adverse reactions include blurred vision, conjunctival hemorrhage, increased intraocular pressure, choroidal neovascularization, eye pain, vitreous floaters, and blepharitis[1].

How does the overall drug price inflation rate affect IZERVAY?

The projected 3.81% drug price inflation rate for 2025 could influence the pricing of IZERVAY, although its specialized nature may keep its price stable or slightly increasing in the short term.

What regulatory efforts could impact IZERVAY's pricing?

Efforts such as the Oregon Drug Price Transparency Program and federal policies like the Inflation Reduction Act could potentially impact the pricing strategy for IZERVAY in the long term[5].

Cited Sources:

  1. DailyMed: IZERVAY- avacincaptad pegol injection - DailyMed.
  2. Vizient: Vizient projects drug price inflation at 3.81%.
  3. ASPE: ISSUE BRIEF - ASPE.
  4. AAPC: NDC Code Lookup - CPT/HCPCS Cross-Reference.
  5. Oregon Drug Price Transparency Program: Prescription Drug Price Transparency Results and Recommendations.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.